Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SUPN
HOLDSupernus Pharmaceuticals, Inc. · Healthcare · United States · $2.7B · Avg Vol: $40M/d
COMPANY DESCRIPTION
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for central nervous system (CNS) disorders, including treatments for epilepsy, ADHD, and Parkinson's disease. The company differentiates itself through proprietary drug delivery technologies that enhance therapeutic profiles. It holds a niche position in the complex CNS market, leveraging its specialized development capabilities.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 667.2M | 607.5M | 661.8M | 719.0M | 2.5% | 776.8M | 867.2M | 1.0B | 19.3% |
| EPS | 1.13 | 0.02 | 1.34 | -0.68 | 8.9% | -0.51 | — | — | — |
| Shares | 54.3M | 54.7M | 55.7M | 57.5M | +5.9% | 58.0M | — | — | — |
| Debt | 444.8M | 41.5M | 34.3M | 41.0M | -54.8% | 40.9M | — | — | — |
| Equity | 886.2M | 921.5M | 1.0B | 1.1B | 6.2% | — | — | — | — |
| Op CF | 116.8M | 111.1M | 172.0M | 47.3M | -26.0% | 83.3M | — | — | — |
| Inv CF | -216.7M | 268.7M | -189.9M | 4.1M | — | — | — | — | — |
| Fin CF | -10.5M | -397.9M | 12.2M | 9.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SUPN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SUPN | Supernus Pharmaceuticals, Inc.(you) | $2.7B | 63 | HOLD |
| CURA.TO | Curaleaf Holdings, Inc. | $2.5B | 51 | HOLD |
| XERS | Xeris Biopharma Holdings, Inc. | $1.4B | 59 | HOLD |
| ETON | Eton Pharmaceuticals, Inc. | $1.2B | 62 | HOLD |
| PBH | Prestige Consumer Healthcare Inc. | $2.4B | 81 | STRONG BUY |
| PAHC | Phibro Animal Health Corporation | $1.4B | 73 | BUY |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.4B | 88 | STRONG BUY |
| LQDA | Liquidia Corporation | $7.7B | 55 | HOLD |
| AMPH | Amphastar Pharmaceuticals, Inc. | $825M | 75 | BUY |
| TRLV | Trulieve Cannabis Corp. | $1.6B | 89 | STRONG BUY |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%